Research.
What the published literature reports on the compounds in our catalog — the trial, the number, the source. Every claim is attributed; nothing here is medical advice or a protocol for use in people.
BioregulatorsCartalax and Chonluten: the bioregulators with almost no published record
Same Khavinson school as Thymalin and Epithalon, a fraction of the evidence. One cell-culture study for Chonluten, no readable efficacy study at all for Cartalax — and that asymmetry is the article.
26 September 2026 · 2 min read
LongevityEpithalon and the telomere claim: what the Khavinson papers actually report
Telomerase reactivation in a dish, extra passages past the Hayflick limit, longer-lived flies and mice — and no modern human trial. The published Epithalon record, figure by figure.
26 September 2026 · 4 min read
PerformanceMyostatin inhibitors: ACE-083 went to phase 2, follistatin-344 never left the lab
One follistatin-based molecule grew muscle in two randomised phase 2 trials and still failed where it mattered. The other has only animal data, a black market, and a retinal case series. The published record, side by side.
26 September 2026 · 4 min read
GLP-1Tirzepatide: what SURMOUNT-1 and SURMOUNT-2 actually showed
Two 72-week placebo-controlled trials, 3,477 participants between them — one in obesity without diabetes, one in obesity with type 2 diabetes. The published weight-loss figures, dose by dose, and where the data stop.
26 September 2026 · 3 min read
RepairARA-290 (cibinetide): four human trials, and the endpoints they missed
This is one of the very few compounds on the repair shelf with real randomised human data — four published trials, including a 64-subject phase 2b. Read them closely and the nerve-regeneration endpoint separates from placebo while the pain endpoint mostly does not.
4 September 2026 · 6 min read
PerformanceExercise mimetics: what AICAR, SLU-PP-332 and 5-Amino-1MQ have actually done, and in what species
One of these three has been given to 3,080 humans — and the trial was stopped for futility. The other two have never been given to a human at all. All three are sold on the same phrase, and the phrase comes from one mouse treadmill experiment in 2008.
4 September 2026 · 6 min read
MetabolicTesofensine: a phase 2 result that never became a phase 3 paper
The 2008 Lancet trial is real, and the numbers in it are large. What followed is the part nobody quotes — an Expression of Concern from the journal, no published phase 3 anywhere in the indexed literature, and no approval in the EU or the US.
4 September 2026 · 6 min read
LongevityEndurance, GlutaMB and the antioxidant pens: the labels add up, the trials are less flattering
Glutathione, NMN, resveratrol and methylene blue, in two pre-mixed pens. One component has a good human trial, one has four negative ones, and one is present at a dose thousands of times below the trial that reported a benefit. Ingredient by ingredient.
2 September 2026 · 5 min read
ProgramsThe four programs: what you are actually buying when you buy one
A program is the manufacturer's own multi-month protocol sold as the set of pens it calls for — priced below the sum of its parts, delivered on one fee. Here is what is in each of the four, and how strong the evidence under each component really is.
2 September 2026 · 4 min read
SleepDSIP: named after an effect that later human work could not reproduce
Isolated from rabbit blood in 1977 and named for the EEG rhythm it enhanced. Four small human insomnia studies produced weak or null results, a 2009 anaesthesia study found it reduced delta rhythm, and no gene or receptor has ever been identified.
1 September 2026 · 3 min read
MetabolicHGH Fragment 176-191 and AOD9604: a well-built mouse story with a missing human chapter
The idea was elegant — take growth hormone's fat-metabolism domain and leave the growth and insulin effects behind. It worked in obese mice, repeatedly. PubMed indexes 23 papers mentioning AOD9604 and not one randomised human trial.
1 September 2026 · 4 min read
GH axisIGF-1 LR3 and PEG MGF: two names, and what is actually published under each
Recombinant IGF-1 is an approved drug with a registry behind it. The LR3 analogue is a cell-culture reagent. PEG MGF has no administration study at all — the human MGF papers measure a gene switching on, not a peptide going in.
1 September 2026 · 4 min read
RepairKPV: three amino acids off the end of α-MSH, and where its evidence actually sits
The mechanism is unusually well worked out — KPV enters cells through PepT1, a transporter that is upregulated exactly where gut inflammation is. Every efficacy result is a mouse or a cell line, and the colitis work was oral, not injected.
1 September 2026 · 4 min read
HormonalPT-141 (bremelanotide): the melanocortin that got an approval — for one indication only
Two phase 3 trials, an FDA-approved product and a published critique of its own endpoints. This is the rare compound where the human data exists, and where reading it carefully changes what you can claim.
1 September 2026 · 3 min read
RepairThe recovery stack: BPC-157 and TB-500, and why they ship in one pen
The most requested pairing in the repair category, in a single pre-filled pen. What each peptide is doing, what the published work actually reports, and why laboratories keep ordering the two together.
27 August 2026 · 4 min read
MetabolicBurnMix and Lipobalance: the metabolic pens for people who want more than one lever
Two multi-pathway fat-loss formulations, opened up compound by compound. What each ingredient is there to do, which ones have human data, which ones do not, and where they sit next to the GLP-1 shelf.
27 August 2026 · 4 min read
Buying guideHow to buy research peptides in Europe: the ten-minute checklist
Six checks that separate a serious European peptide supplier from a drop-shipper with a nice logo — and how to run them on any shop, including this one, before you spend anything.
27 August 2026 · 4 min read
OrderingFrom checkout to doorstep: how a peptide order actually moves inside the EU
Same-day processing, tracked delivery in about four days, a plain unbranded box, and one flat fee per order. Here is every step of a European peptide delivery, including what happens when it goes wrong.
27 August 2026 · 4 min read
GH axisIpamorelin and CJC-1295: the GH-axis pairing labs ask for by name
Two doors into the same output, in one pre-filled pen. Why this combination became the default in growth-hormone research, what the human data covers, and the label detail almost every shop gets wrong.
27 August 2026 · 4 min read
LongevityThe longevity pens: CellDetox and Everlong, and what is really inside them
Senolytics, exosomes, NAD+, glutathione, resveratrol — the two most advanced formulations in our catalog, ingredient by ingredient, with the research that supports each one and the research that does not exist yet.
27 August 2026 · 4 min readPaymentsPaying with USDT, USDC or a bank transfer: how checkout works here
Two payment rails, no cards, no third-party checkout script. What each one costs you in time, why the crypto amount has to be exact, and which one to pick if you want the parcel moving today.
27 August 2026 · 4 min read
SkinThe skin shelf: GHK-Cu and Radiance, copper versus copper-free
One peptide with fifty years of literature, one modern complex built without copper, and a third pen aimed at blemish-prone skin. What is in each, which claims are backed, and how to choose between them.
27 August 2026 · 4 min read
Catalog guideFour departments, twelve shelves: a plain map of the catalog
Peptides, performance compounds, SARMs and programs — what each shelf is actually for, which compounds sit on it, and which article to read before you order from it.
27 August 2026 · 3 min read
ManufacturersNordic Peptides, Med Care Pharma, Marvel Nutrition, PharmaRx: who makes what we ship
Four manufacturers, four very different houses. Which one made the box that arrives, what each of them publishes about their own material, and where each is honestly weaker.
27 August 2026 · 3 min read
BlendsBlends: when a combined pen is the right call, and when it costs you the answer
Klow, MitoBoost, Retabolic — three compounds in one pen, at a lower price than buying the parts. Here is the honest trade you are making when you take it.
23 August 2026 · 2 min readSkin & repairGHK-Cu: the copper peptide with fifty years of literature behind it
Isolated from human plasma in 1973, studied continuously since, and one of the few compounds in this catalog where the human evidence is topical, comparative and reasonably old.
23 August 2026 · 2 min read
GH axisGHRP-2, GHRP-6 or ipamorelin: three ghrelin-receptor peptides, three different side profiles
All three hit the same receptor and all three release growth hormone. What separates them is everything else they do on the way — appetite, cortisol, prolactin.
23 August 2026 · 3 min readGLP-1The GLP-1 line, compared: semaglutide, tirzepatide, retatrutide
One receptor, two, or three. Here is the whole line side by side — the trial numbers, the trade-offs and which pen sits where in our catalog.
23 August 2026 · 2 min readQualityHow to read a certificate of analysis (and how to catch a fake one)
A COA is a document about one batch, on one day, from one lab. Most of what circulates as 'lab tested' in this market fails that sentence in at least two places.
23 August 2026 · 3 min readHandlingWhy everything in our peptide line ships as a pen, not a vial
Vials are cheaper to buy and cheaper to sell. They are also where the errors live. Here is the measured difference, and why we made the call the way we did.
23 August 2026 · 3 min readGLP-1Retatrutide 6, 12, 20 or 30 mg: which pen, and why four of them exist
The four strengths are not four products. They map onto how the phase 2 trial was escalated — and onto how much material a given protocol actually consumes.
23 August 2026 · 3 min read
SARMsSARMs: the phase 3 exists, and it missed its endpoints
This class is usually sold with the word 'clinical' attached. There is real clinical work behind it — two phase 3 trials — and knowing what they found is the difference between an informed buyer and a marketed-to one.
23 August 2026 · 3 min read
NeuroSemax and Selank: two Russian peptides with a literature problem
Both are approved medicines in Russia. Both have decades of clinical use behind them. Almost none of that work is readable in English, and that gap is the honest headline.
23 August 2026 · 3 min readHandlingWhat actually degrades a peptide (and why we don't ship on ice)
The cold-chain theatre in this market is mostly theatre. Here is what the manufacturers themselves specify, what really damages a peptide, and the one product in our catalog that is an exception.
23 August 2026 · 3 min read
BioregulatorsThymalin and the Khavinson bioregulators: forty years of data from one institute
The longest human follow-up of any compound in this catalog — 266 elderly patients over six to eight years — and the reason mainstream medicine still has not acted on it.
23 August 2026 · 2 min readRepairBPC-157: what the evidence actually says
Thirty-five preclinical studies, one clinical study. That ratio is the whole story of BPC-157 — a compound with a large and fairly consistent animal literature and almost no human data behind it.
21 August 2026 · 3 min readGLP-1Retatrutide: what the phase 2 data actually show
A triple receptor agonist that produced the largest weight reductions yet published for a single obesity drug — 24.2% at 48 weeks. Here is what the trial measured, and what it did not.
21 August 2026 · 3 min readGLP-1Tirzepatide vs semaglutide: the first head-to-head trial
For years the comparison was made across separate studies, which is not a comparison at all. In 2025 the two were finally run against each other in the same trial — 751 participants, 72 weeks, one protocol.
21 August 2026 · 3 min read
GH axisCJC-1295 and ipamorelin: two mechanisms, one very common confusion
The pairing is the most requested combination in the GH-axis line. It is also the one where the label on the vial and the study people quote are frequently not the same molecule.
19 August 2026 · 3 min readMetabolicMOTS-c: the peptide your mitochondria write themselves
A 16-amino-acid peptide encoded inside mitochondrial DNA, released by exercise, and falling with age. The mechanism is elegant and well documented — in mice.
19 August 2026 · 2 min read
MetabolicNAD+, NMN and nicotinamide: three different molecules, one marketing word
The NAD category is sold as if it were one product. It is not — and the one human randomised trial in the field tested a specific precursor, at a specific dose, in a specific population.
19 August 2026 · 2 min readGLP-1Semaglutide: what the STEP programme showed — and what happened when people stopped
14.9% at 68 weeks made semaglutide famous. The trial extension, which gets far less attention, is the part that explains what the drug actually does.
19 August 2026 · 3 min read
RepairTB-500 and thymosin β4: the clinical trials are real, but they are eye drops
Thymosin β4 has been through randomised, placebo-controlled human trials — including a phase 3. Almost none of that work involves the injectable fragment sold as TB-500, and the difference is the whole story.
19 August 2026 · 2 min read
GH axisTesamorelin: the one growth hormone peptide with an approval behind it
Of every GHRH-class compound sold as research material, exactly one has been through phase 3 and cleared by the FDA. Here is what that trial measured — and why the indication is narrower than the internet suggests.
19 August 2026 · 3 min read